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The components of the PI3K/Akt pathway
Th   ere are three principal components of the Akt 
pathway: phosphatidylinositol 3-kinase (PI3K), its anta-
go  nist PTEN (phosphatase and tensin homologue deleted 
on chromosome ten), and the serine/threonine kinase 
Akt, which is expressed as three diﬀ  er  ent isoforms, Akt1, 
Akt2, and Akt3, which are structurally similar but 
transcribed from diﬀ  erent genes [1]. Th   ese isoforms have 
distinct expression patterns and functions. Downstream 
substrates of activated Akt include the serine/threonine 
kinase mammalian target of rapamycin  (mTOR) and the 
Forkhead family of transcription factors (FOXO).
Th  e kinase activity of Akt is dependent upon phos-
phorylation of threonine 308 and serine 473. Th   is is most 
often mediated by class IA PI3K, a member of the family 
of intracellular lipid kinases that are activated by growth 
factor RTKs (receptor tyrosine kinases) such as insulin 
receptor, insulin-like growth factor receptor (IGF-1R), 
platelet-derived growth factor receptor (PDGFR), and 
members of the epidermal growth factor (EGF)/ErbB 
family in addition to G protein-coupled receptors and 
oncogenes such as Ras. Other classes of PI3K do not 
activate Akt and will not be discussed further. At the 
plasma membrane, PI3K phos  phorylates the 3’-hydroxyl 
group of phosphatidyl  inositol 4,5 diphosphate (PIP2) to 
generate phosphatidyl  inositol-3,4,5-trisphosphate (PIP3), 
a lipid second messenger that binds to the pleckstrin-
homology (PH) domains of down  stream target molecules 
such as 3-phos  phoinositide-dependent kinase 1 (PDK1) 
and Akt. Th   is results in autophosphorylation of PDK1 at 
Ser241 within its activa  tion  loop, resulting in the 
transphosphorylation of Akt (Figure  1) in addition to 
other serine/threonine kinases, including PKC, ribosomal 
p90 S6 kinase (S6K), and SGK. Th  e Rac/Cdc42 kinase, 
PAK1, and the Rho kinase, PKN/PKC-related kinase 1, 
which are associated with invasion and metastasis, are 
also activated by PDK1.
In addition to PDK1-mediated Th  r308  phosphorylation, 
phosphorylation on Ser 473 by the mTOR-rictor kinase 
complex is required for full activation of Akt, which 
leads, in turn, to phospshorylation of Akt targets such as 
the FOXO family of transcription factors. FOXO proteins 
are inactivated by Akt phosphorylation, resulting in their 
binding to, and sequestration in the cytoplasm by, 14-3-3 
proteins. FOXO target genes include the pro-apoptotic 
BH3-only protein Bim and the DR (death receptor) ligand 
FasL [2].
Of the three classes of PI3Ks, class IA and its compo-
nents are most frequently the target of mutations in 
cancer. Indeed, this pathway is unusual in that all of its 
major components are either mutated or ampliﬁ  ed in a 
wide range of cancers. Class IA PI3Ks are obligate hetero-
dimers of a p85 regulatory subunit and a p110 catalytic 
subunit. In the mouse, there are three catalytic subunits 
(p110α, β, and γ) and ﬁ   ve regulatory subunits (p85α, 
p55α, p50α, p85β, and p55γ), whereas in Drosophila 
melanogaster, there is one catalytic and one regulatory 
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subunits to phosphotyrosine (pY) residues in either the 
cytoplasmic tail of the receptor or receptor-bound 
adaptors and signalling molecules such as Stat3 [4]. Th  e 
three α regulatory subunits are encoded by the same gene 
(pik3r1) but transcribed from diﬀ   erent promoters, at 
least in mammary gland. Th   e regulatory subunits 
stabilize, but inhibit, the catalytic subunits unless bound 
to pY motifs.
PTEN, as its name suggests, is a phosphatase that 
reverses the action of PI3K by dephosphorylating PIP3, 
thereby regulating Akt activity and downstream respon  ses 
[5]. PTEN has phosphatase, C2, and PDZ-binding domains 
and has recently been shown to shuttle between the 
nucleus and cytoplasm in response to its phosphory  lation 
status, which may contribute to its ability to modulate cell 
growth and viability. Several kinases have been reported to 
phosphorylate PTEN [6]. Recently, the Fyn-related kinase 
FRK, a member of a small family of intracellular 
Src-related tyrosine kinases, has been shown to 
phosphorylate PTEN, suppressing its association with the 
E3 ubiquitin ligase NEDD4-1, thereby reducing poly-
ubiquitination and proteosomal degradation of PTEN [7].
Functions of PI3K/Akt pathway
One of the most important functions of Akt is in the 
regulation of glucose homeostasis and metabolism, 
particularly in muscle and fat. Uptake of glucose via the 
glucose transporter GLUT4 is facilitated by translocation 
of GLUT4 to the plasma membrane in response to Akt. 
Akt also inhibits GSK3 (glycogen synthase kinase 3), 
thereby activating glycogen synthase, and activates ATP 
citrate lyase, thereby regulating fatty acid synthesis. 
Given the importance of adipose tissue and its re-
modelling during a pregnancy/lactation/involution cycle, 
it would be anticipated that Akt would have a critical role 
to play in mammary gland. Indeed, this has been found to 
be the case, as discussed below.
Figure 1. Signalling from receptor tyrosine kinases to Akt is mediated by PI3kinase regulatory subunits and adaptor molecules that 
activate PI3K, which in turn converts PIP2 to PIP3. FOXO, Forkhead family of transcription factors; GSK3, glycogen synthase kinase 3; IGF 
1/2, insulin-like growth factor 1/2; IL-6, interleukin-6; IRS, insulin receptor substrate; mTOR, mammalian target of rapamycin; NF-κB, nuclear 
factor-kappa-B; P, phosphate; PDK1, 3-phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5 
diphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; RTK, receptor tyrosine kinase; S6K, S6 kinase.
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Page 2 of 9Akt regulates transition through the cell cycle by 
inhibiting the transcriptional activity of FOXO, which 
has a number of cell cycle regulatory proteins as its 
targets. Th  ese include the cell cycle inhibitor p27 and 
RBL2 (retinoblastoma-like 2). Akt is a survival factor, 
regulating the expression of FasL and Bim via FOXO. In 
addition, Akt directly phosphorylates the pro-apoptotic 
protein Bcl2 antagonist of cell death (BAD), causing its 
inactivation by binding to 14-3-3 protein, and phos-
phorylates the p53 regulator MDM2, leading to p53 
degradation. Furthermore, the nuclear factor-kappa-B 
(NF-κB) family of transcription factors can be activated 
downstream of PI3K by a mechanism that requires 
association of the regulatory p85α subunit through its 
SH2 domain with inhibitor of kappa-B alpha (IκBα) [8]. 
Additional pathways activate NF-κB via Akt association 
with inhibitor of kappa-B kinase (IKK), resulting in IKK 
activation and phosphorylation of IκB [9]. NF-κB regulates 
a wide range of cellular responses, including growth and 
survival, and is a critical regulator of inﬂ  ammatory 
signalling. More recently, it has been shown that Akt-
dependent regula  tion of NF-κB requires mTOR and 
Raptor [10]. Akt regulates protein synthesis by 
phosphorylating the tuberous sclerosis complex 2 (TSC2) 
protein tuberin, thus inhibiting the GAP (GTPase-
activating protein) activity of the TSC1-TSC2 complex 
toward Rheb (small G protein Ras homologue enriched in 
brain). GTP-bound Rheb accumulates and activates the 
mTOR-Raptor kinase complex, which in turn mediates 
phosphorylation of 4E-BP1 (eukaryotic translation 
initiation factor 4E-binding protein 1) and p70S6Kinase, 
ultimately leading to increased protein synthesis [2].
Finally, PI3K regulates cell polarity and motility in 
concert with the small GTPases Rac, Rho, and Cdc42 by 
controlling actin dynamics in motile cells [11]. All four 
catalytic subunits of PI3K are implicated in cell migra-
tion, and p110α has been associated with increased 
invasiveness in a variety of tumors. Th  ese functions of 
PI3K/Akt are illustrated in Figure 2.
The role of PI3K pathway components and Akt 
isoforms in mammary gland development
As mentioned above, it can be anticipated that the PI3K/
Akt pathway would have important functions in 
mammary gland development and function. Th  e  genera-
tion of genetically altered mice either deﬁ  cient for, or 
expressing constitutively active forms of, speciﬁ  c pathway 
components has revealed their function in the context of 
mammary gland development. Th  e three Akt isoforms 
are perhaps the most studied components of the pathway.
Akt isoforms
Akt1 is required for eﬃ     cient lactation to support 
oﬀ   spring, and deletion of Akt1 results in a failure to 
localize Glut1 at the plasma membrane, reducing glucose 
uptake. In addition, upregulation of lipid synthesis and 
lipogenic enzymes and downregulation of lipid catabolic 
enzymes do not occur in Akt1 knockout mice [12].
Expression of a constitutively active Akt1 that mimics 
the active phosphorylated state of the protein results in a 
delayed post-lactational regression (involution) [13]. A 
later study showed that expressing a membrane-targeted 
form of Akt1 (myr-Akt) under the control of the mouse 
mammary tumor virus (MMTV) promoter resulted in a 
lactation defect in addition to delayed involution. Preco-
cious accumulation of cytoplasmic lipid droplets 
occurred in the alveolar epithelium of MMTV-myr-Akt 
transgenic mice during pregnancy and this resulted in 
stunted growth of the pups, which were 50% smaller 
during the ﬁ  rst 9 days of lactation. Since the fat content 
of milk from the lactating transgenic dams was more 
than double that of non-transgenic controls, it has been 
suggested that this high-viscosity milk reduced suckling 
by the pups [14]. A striking delay in involution was 
observed also in two independent studies of Akt1 over-
expression in mammary gland. Th  e reduced cell death 
was associated with prolonged expression of TIMP-1 
(tissue inhibitor of metalloproteinase-1) and increased 
phosphorylation of Th  r308 in Akt1 and Ser136 in BAD 
[15,16]. Notably, overexpression of Akt1 alone is insuﬃ   -
cient to induce transformation, although expression of 
activated Akt does accelerate tumor development [13].
Akt1 and Akt2 appear to have opposing functions in 
mammary gland since ablation of Akt1 delayed develop-
ment and diﬀ  erentiation during pregnancy and lactation 
whereas Akt2 deﬁ  ciency resulted in precocious diﬀ  eren-
tiation. Likewise, although involution is accelerated in 
the absence of Akt1, it is delayed in Akt2-deﬁ  cient 
mammary glands. Akt3 seems to have a minor role [17]. 
In another study, transgenic mice expressing an activated 
Atk2 (Akt2-DD) in the mammary epithelium showed 
that activated Akt2 expression delayed mammary gland 
involution [18], as was seen for activated Akt1. Th  is 
discrepancy could be related to a requirement for Akt2 in 
non-epithelial cells as transplantation  experiments 
showed this eﬀ  ect to be non-epithelial cell-autonomous. 
Th   is is not surprising given the role of insulin signalling 
in adipose tissue. Indeed, both Akt1 and Akt2 have 
important roles in adipocyte diﬀ  erentiation as demon-
strated by studies in double-knockout mice [19]. 
Whether this is true also for adipocytes in the mammary 
fat pad remains to be determined. Preliminary studies 
from our laboratory indicate that Akt2 is expressed 
predominantly in adipocytes, and not the epithelium, 
during involution. Akt1 and Akt2 have diﬀ  erent eﬀ  ects 
also on cell migration. Activation of Akt1 prevents an 
epithelial-to-mesenchymal transition (EMT), an event 
required for metastasis, and decreases motility and 
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NFAT (nuclear factor of activated T cells) transcription 
factor [20]. Th   is result is supported by experiments using 
siRNA (short interfering RNA)-mediated knockdown of 
Akt1, but not Akt2, in the non-transformed breast 
epithelial cell line MCF-10A in three-dimensional (3D) 
matrigel cultures [21]. Hyperstimulation of IGF-1R 
resulted in 3D acini that had ﬁ  lled, rather than hollow, 
lumens. Lumen ﬁ   lling was reverted by Akt2 down-
regulation that blocked hyperproliferation and the anti-
apoptotic activities of IGF-1R overstimulation, while 
reduction of Akt1 enhanced cell migration and produced 
an EMT-like morphological change [21]. Th  ese  diﬀ  ering 
roles are observed also in studies in mouse tumor models, 
as discussed below.
Interestingly, deletion of Akt1, but not Akt2 or Akt3, 
interferes with the phosphorylation of Stat5a during late 
pregnancy and lactation. Although overexpression and 
hyperactivation studies need to be interpreted with 
caution, it is clear that the three isoforms of Akt have 
diﬀ  erent roles in mammary gland development. Further 
work is needed to determine the cell-type speciﬁ  city of 
Akt isoform function in mammary gland.
PI3K subunits
Th   e three catalytic subunits p110α, p110β, and p110δ are 
all expressed throughout a mammary developmental 
cycle [22]. Transgenic mice in which a myristoylated 
p110α protein was expressed under the control of the 
MMTV promoter exhibited delayed mammary gland 
involution and changes in ductal morphology in young 
mice [23]. Th   e role of the other catalytic subunits has not 
been directly addressed as loss of p110α and p110β 
results in embryonic lethality, precluding analysis of their 
roles in mammary gland [3].
Th   e two small regulatory subunits p55α and p50α have 
an unexpected function in involuting mammary gland 
[22]. Th  e expression of these subunits is dramatically 
upregulated by Stat3 during involution and this is 
associated with a decrease in the levels of pAkt. Over-
expression of individual isoforms in mammary epithelial 
cells resulted in elevated apoptosis, suggesting that Stat3 
Figure 2. Signals feeding into Akt and their relay to downstream target molecules and cellular processes. DR, death receptor; FOXO, 
Forkhead family of transcription factors; GSK3, glycogen synthase kinase 3; IGF 1/2, insulin-like growth factor 1/2; IKKβ/2, inhibitor of kappa-B kinase 
β/2; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-kappa-B; P, phosphate; PDK1, 3-phosphoinositide-dependent kinase 1; PI3K, 
phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5 diphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PTEN, phosphatase and 
tensin homologue deleted on chromosome ten; S6K, S6 kinase; TSC1/2, tuberous sclerosis complex 1/2.
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levels of the p55α/p50α subunits to reduce pAkt-
mediated survival signalling by competition with p85α 
for the catalytic subunits [24].
PTEN
Overexpression of PTEN, as the predominant negative 
regulator of PI3K, would be expected to promote apoptosis 
and involution and possibly also to aﬀ  ect diﬀ  erentiation 
during pregnancy. Th   is was investigated using a transgenic 
mouse model in which human PTEN over  expression was 
driven by the MMTV promoter (MK-PTEN) in ductal and 
alveolar mammary epithelium during a pregnancy cycle. 
Lactation was abnormal in MK-PTEN females, with about 
one third of the pups dying and the survivors displaying 
growth retardation [25]. Th  is was the consequence of 
reduced diﬀ  erentiation of the alveoli and suppressed milk 
protein gene expression and was associated with a 
decrease in the levels of pAkt. Th   e reciprocal experiment 
was carried out by conditional deletion of PTEN in 
mammary epithelium and resulted, not surprisingly, in a 
reciprocal phenotype. In addition to excessive ductal 
branching, precocious lobuloalveolar development during 
pregnancy and delayed involution, coupled with reduced 
apoptosis, were observed [26]. Importantly, PTEN-null 
mammary epithelial cells were hyperproliferative, resulting 
in the early development of mammary tumors.
A role for PTEN in tissue architecture was elegantly 
demonstrated using 3D acinar cultures of mammary 
epithelial cells. PTEN was shown to co-localize at cell-
cell contacts with the E-cadherin/beta-catenin complex. 
Reduction of PTEN levels by shRNA (short hairpin RNA) 
in laminin-rich extracellular matrix cultures prevented 
formation of properly organized acini, and conversely, 
blocking cell-cell contact using E-cadherin function-
blocking antibodies reduced the levels of endogenous 
PTEN, suggesting a role for PTEN in cell adhesion [27].
IGF, insulin, and receptor tyrosine kinases
IGF ligands regulate ductal outgrowth and  branching 
during puberty and are required also for alveolar 
development during  pregnancy [28]. Th   e IGF-1R is 
essential for proliferation in TEBs (terminal end buds) 
during puberty, while overexpression disrupts develop-
ment and can lead to tumorigenesis [29]. Th  e role of 
insulin in mammary gland development is less well 
understood. Insulin receptor-A binds IGF-II in addition to 
insulin but does not bind IGF-I. However, IGF-II 
stimulates the PI3K pathway more eﬃ   ciently than insulin 
and appears therefore to be the most important mediator 
of IGF signalling [30]. Interestingly, either injection of 
IGF-II into mouse mammary glands or overexpression in 
a transgenic model resulted in increased expression of 
PTEN and concomitant downregulation of pAkt levels.
The downstream eff  ectors of Akt: switches in 
mammary gland development
As mentioned above, Akt has a considerable number of 
downstream targets that control diﬀ  erent  cellular 
processes. It is not clear how these are integrated at the 
Akt hub to dictate the outcome, although the role of 
individual targets has been extensively investigated. 
Th   ere are a limited number of studies on speciﬁ  c roles in 
mammary gland, although given the changes in pAkt 
levels at the lactation/involution switch and the prolifera-
tion/diﬀ  erentiation switch in pregnancy, it is likely that 
many of these targets are important. A diagrammatic 
summary of the signals leading into and emanating from 
Akt is shown in Figure 2. An extensive discussion of each 
of these targets is beyond the scope of this review but is 
reviewed elsewhere [2]. It is worth noting that cyclin D1 
and NF-κB have both been shown to be important in the 
development of the mammary gland during pregnancy 
[31,32].
What are the consequences of PI3K pathway 
mutations for mammary tumorigenesis?
Given the importance of the PI3K/Akt pathway in 
regulating proliferation, diﬀ  erentiation, and apoptosis of 
mammary epithelial cells, inappropriate activation of this 
pathway by genetic mutation or ampliﬁ   cation of key 
signal  ling components could be anticipated to result in 
tumorigenesis. Furthermore, the most eﬀ  ective type of 
therapy for breast cancer is likely to depend on the mode 
of activation and the function of the particular pathway 
component that is aberrantly activated. Most studies fall 
into two categories: modiﬁ  cation of PI3K signalling in 
mouse mammary tumor models or determination of the 
activity of pathway components in breast cancer tissue 
samples. Th   e most informative mouse modelling studies 
are discussed ﬁ  rst. Notably, overexpression of Akt1 alone 
is not suﬃ   cient  to  induce  tumorigenesis [16] and co-
operating oncogenes are required to elicit tumorigenic 
eﬀ  ects.
AKT
Studies in transgenic mice suggest that Akt1 and Akt2 
have distinct roles in mammary tumor induction in two 
commonly used tumor models, activated ErbB2 (NDL) 
and polyoma virus middle T antigen (PyVmT). In NDL/
activated Akt1 crosses, tumorigenesis is accelerated but 
the tumors have a more diﬀ  erentiated phenotype and 
invasion is suppressed [33]. Th  is corresponds to a 
reduction in the number of metastatic lesions compared 
with NDL strain alone. In both of these tumor models, 
deletion of Akt1 resulted in a dramatic defect in tumor 
induction, while in contrast, tumorigenesis was 
accelerated in Akt2-deﬁ   cient mice. Overexpression of 
constitutively active Akt1 in PyVmT/PI3K-independent 
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observed also for NDL transgenics. Overexpression of 
constitutively active Akt2 in the same two tumor models 
did not aﬀ  ect tumor latency but did, however, increase 
lung metastasis. Th  us, as seen for normal mammary 
gland development, Akt1 and Akt2 have diﬀ  erent roles in 
mammary tumorigenesis and metastasis [18]. A further 
insight into mechanisms by which the balance of Akt1 
and Akt2 controls metastasis was revealed by microRNA 
proﬁ   ling of cells triple-null for Akt1/2/3 that were 
transfected with individual Akt isoforms. Expression of 
the miR-200 family was decreased in cells expressing 
Akt2 or with knockdown of Akt1 expression, the latter 
associated with an EMT [34]. Th  is led the authors to 
suggest that EMT is controlled by the abundance of 
miR-200 microRNAs that are regulated by the relative 
amounts of Akt1 and Akt2.
In another study, MMTV-myr-Akt1 transgenic mice 
were crossed with MMTV-c-ErbB2 transgenic mice and 
a similar acceleration in tumor development was ob-
served. Th   e presence of activated Akt1 did, however, have 
an inﬂ   uence on the expression and activation of EGF 
receptor (EGFR) family members. Th  e MMTV-c-ErbB2 
tumors overexpressed EGFR, ErbB2, ErbB3, and ErbB4 
and exhibited phosphorylation of both ErbB2 and ErbB3, 
whereas tumors from the bitransgenic mice had drama-
tically less overexpression and phosphorylation of ErbB3, 
diminished phosphorylation of ErbB2, a decreased level 
of EGFR protein, and undetectable ErbB4 protein [35]. 
Th   is result suggests that ErbB2-targeted therapies would 
be less eﬀ  ective when an additional mutation/activation 
of Akt1 is also present in the tumor.
PI3K
PI3K can be activated when p110α is forced to localize at 
the plasma membrane by myristoylation. Transgenic 
mice expressing myrp110α had increased ductal 
branching, alveolar hyperplasia, and intraductal neo-
plasia, which occasionally resulted in mammary tumors. 
It is worth noting that the tumors that arose in myrp110α 
transgenic mice had increased phosphorylation of 
estrogen receptor α, a feature of breast cancer [23].
PTEN
PTEN mutations are uncommon in breast cancer, aﬀ  ect-
ing only about 5% of patients. Reduced expression of 
PTEN at the protein level is much more common and 
occurs in 30% to 50% of patients, generally correlating 
with a less favorable outcome. Consistent with its func-
tion as a tumor suppressor, loss of heterozygosity (LOH) 
of Pten is frequent and loss of both alleles is a feature of 
metastatic disease. Low expression of PTEN also corre-
lates with unresponsiveness to breast cancer therapies 
such as trastuzumab (Herceptin), tamoxifen, and geﬁ  tinib.
In mice, mutations in Pten  do not usually lead to 
mammary carcinoma. However, crosses of PTEN hetero-
zygous mice to MMTV-Wnt-1 transgenic mice accel-
erated the onset of ductal carcinomas compared with 
control MMTV-Wnt-1 transgenic mice and this was 
associated with elevated levels of pAkt [36]. Furthermore, 
the majority of the tumors lost the remaining Pten allele, 
indicating a growth advantage for the PTEN-null tumor 
cells.
Co-operation between PTEN and ErbB2 was investi-
gated by crossing transgenic mice harboring a Cre-
inducible activated erbB-2 under the control of the 
endogenous erbB-2 promoter (ErbB-2KI) to mice with 
ﬂ  oxed PTEN alleles and MMTV-driven Cre recombinase 
[37]. Deletion of a single allele of Pten not only accel-
erated ErbB-2-induced mammary tumor progression but 
increased lung metastases. Interestingly, PTEN-deﬁ  cient/
ErbB-2KI mammary tumors were heterogeneous, with 
some cells having characteristics of basal cells such as 
SMA expression. PTEN deﬁ  ciency also promoted ErbB2-
mediated tumorigenesis in a mouse model using the 
MMTV promoter to drive expression of activated ErbB-2 
and Cre recombinase in the same cells. Multifocal, highly 
metastatic tumors were formed in concert with increased 
pAkt and angiogenesis [38]. Interestingly, in this scenario, 
the tumors displayed molecular and histopathological 
features of the luminal subtype. Recently, it has been 
demonstrated that loss of PTEN in stromal ﬁ  broblasts 
accelerates the initiation, progression, and transformation 
of mammary epithelial tumors [39].
PDK1
PDK1 has been shown to be oncogenic in Comma-1D 
mouse mammary epithelial cells, and Pten+/– tumor [40] 
formation was  severely attenuated when bred with 
Pdpk1 hypomorphic mice that had only 10% of normal 
PDK1 enzyme activity. A non-catalytic role for PDK1 in 
cancer cell motility involves direct binding to ROCK1 
and localization at the plasma membrane, where it is 
required to drive cortical acto-myosin contraction and 
cell motility [41].
FOXO and mTOR
Several studies have demonstrated that rapamycin, which 
inhibits mTOR, a downstream target of Akt, sensitizes 
certain resistant cancer cells to chemotherapeutic agents. 
Th  e  eﬃ   cacy of mTOR inhibition was analyzed in MCF-7 
breast cancer cells, expressing a constitutively active Akt, 
that are resistant to the growth inhibitory eﬀ  ects  of 
tamoxifen. It was found that treatment with rapamycin 
restored sensitivity to tamoxifen and blocked estrogen 
receptor-α-mediated transcriptional activity [42].
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cancers
A variety of diﬀ  erent types of mutations, including gene 
ampliﬁ  cation, mutation, and LOH, have been found in 
breast tumors in diﬀ  erent components of the PI3K/Akt 
pathway. Epigenetic changes that reduce expression are 
also likely but are not usually detected in mutation 
analyses. Th  e types of mutations and their frequencies 
are listed in Table 1.
Mutations in p110α occur in around 35% of breast 
tumors. One study revealed more than 20 diﬀ  erent 
mutations, at diﬀ  erent frequencies, in p110α (encoded by 
the PI3KCA gene) in breast cancers. Th   e biological eﬀ  ect 
of individual mutations was assessed by using lentivirus 
to express 10 of these mutant PIK3CA genes in the 
human breast epithelial cell line MCF10A. Expression of 
most of the mutations resulted in morphological changes 
in MCF10A cells in 3D acinar culture, diﬀ  erentially 
promoted cell invasion, and activated p-AKT and 
p70-S6K in the absence of EGF stimulation [43].
Another frequently mutated gene is PDPK1, usually 
resulting in overexpression as a result of gene ampliﬁ  -
cation. Approximately 1 in 5 breast tumors have at least 5 
copies of the PDK1 gene, PDPK1, and the increased copy 
number is associated with additional upstream mutations 
such as ErbB2 ampliﬁ   cation, PTEN loss, or PI3K 
mutation. In orthotopic transplantation models, over-
expression of PDK1, though not oncogenic by itself, 
dramatically enhanced ErbB2-mediated tumorigenesis 
[44]. Two previous reports, using immunohistochemistry 
analysis, suggested  increased phosphorylated PDK1 
Table 1. The type and frequency of mutations in 
phosphatidylinositol 3-kinase (PI3K) pathway components 
in breast cancer
PI3K component  Type of mutation  Incidence
p110α (PIK3CA)  Mutation  27%
p110α (PIK3CA)  Amplifi  cation  8.7%
P110β (PIK3CB)  Amplifi  cation  5%
PDPK1  Amplifi  cation and overexpression  20%
AKT1 Mutation  (E17K)  3.7%
AKT2 Amplifi   cation  3%
PTEN  Loss of heterozygosity  24.9%
PTEN Mutation  6%
Figure 3. Therapeutic drugs that target various components of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. EGFR, epidermal 
growth factor receptor; HER2, human epidermal growth factor receptor 2; mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial 
growth factor receptor.
EGFR HER2 VEGFR
PI3K
Akt
mTOR
Vandetanib
Trastuzumab (Herceptin)
Mubritinib
Pertuzumab
Canertinib
Ertumaxomab
HKI-272
Bevacizumab
Pazopanib
Lapatinib
EKB-569
Gefitinib (Iressa)
Erlotinib (Tarceva)
Cetuximab
Panitumumab
Matuzumab
Nimotuzumab
MAb-806
MDX-447
BEZ235
BGT226
XL765
SFI126
BKM120
XL147
GDC0941
GSK1059615
PX-866
CAL101
Perifosine
MK2206
VQD-002
XL418
Rapamycin
CCI-779
RAD001
AP23573
AZD8055
OSI-027
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Page 7 of 9protein levels in the majority of human breast cancers. 
Th   us, alterations in the levels of PDK1 protein seem to be 
an important factor in breast cancer.
Although mutations in PTEN are rare, LOH is a 
common feature of breast cancers, being observed in 
approximately 25% of tumors. Mutations in Akt1 and 
ampliﬁ  cation of Akt2 are infrequent, although a speciﬁ  c 
mutation in the PH domain of Akt1 that results in a 
glutamic acid-to-lysine substitution in its lipid-binding 
pocket has been found in breast, colorectal, and ovarian 
cancers [45].
Cytoplasmic localization of FOXO3a is associated with 
a poor survival rate in breast cancer patients and has 
been shown to be correlated with expression of IKKβ or 
pAkt. Interestingly, IKKβ-mediated tumorigenesis can be 
suppressed by FOXO3a [46].
Therapies directed against activating mutations in 
PI3K pathway
Although the PI3K inhibitors wortmannin and LY294002 
can inhibit tumor growth, they have high toxicity, thus 
limiting their clinical usefulness. A more potent and less 
toxic derivative of wortmannin, PX-866, has been tested 
and shown to be eﬀ  ective in xenograft studies, but the 
lack of speciﬁ  city of these inhibitors is likely to render 
them unsuitable for therapy. Reconstitution or over-
expression of PTEN activity could be an approach to 
counteracting PI3K activity and has been shown to 
reduce Wnt-induced mammary hyperplasia. Adenoviral 
delivery of PTEN is a potential option in the clinic and 
can induce apoptosis in xenografts of colon carcinoma 
cells [47].
Rapamycin analogues are currently in clinical trials. 
Th   ese might be eﬀ  ective in treating cancers with p110α 
or PTEN mutations since Akt is already active, but are 
less likely to be eﬀ  ective in cancers in which PI3K activa-
tion is negatively regulated by mTOR. Inhibition of 
mTOR has been shown to restore the response to 
tamoxifen in breast cancer cells that have aberrantly 
activated Akt [42]. A potential problem with inhibiting 
p110α, since it is a key mediator of insulin signalling, 
could be type II diabetes. Another possibility is isoform-
speciﬁ   c inhibition of Akt. Combination therapy with 
EGFR or ErbB2 inhibitors could lead to side eﬀ  ects that 
are less toxic. Th  erapeutic drugs currently in use or in 
clinical trial against diﬀ  erent components of the PI3K 
pathway are shown in Figure 3.
Conclusions
Th  e PI3K/Akt pathway is frequently dysregulated in 
breast cancer as a result of mutation, ampliﬁ  cation, or 
deletion of diﬀ   erent components of the pathway. 
Although a number of drugs are available, the essential 
function of Akt as the intracellular hub that integrates 
signals from growth factors to control metabolism, protein 
synthesis, growth, and cell survival-death deci  sions 
presents unique challenges for the design of drugs with 
few oﬀ  -target eﬀ  ects.
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